Badanie The Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Controlled Evaluation (ADVANCE) – korzyści wypływające z intensywnego leczenia hiperglikemii u chorych na cukrzycę typu 2
Drzewoski J. The Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Controlled Evaluation (ADVANCE) – the benefits of hyperglycaemia intensive treatment in patients with type 2 diabetes mellitus. Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review. 2008:254-259.
APA
Drzewoski, J. (2008). The Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Controlled Evaluation (ADVANCE) – the benefits of hyperglycaemia intensive treatment in patients with type 2 diabetes mellitus. Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review, 254-259.
Chicago
Drzewoski, Józef. 2008. "The Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Controlled Evaluation (ADVANCE) – the benefits of hyperglycaemia intensive treatment in patients with type 2 diabetes mellitus". Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review: 254-259.
Harvard
Drzewoski, J. (2008). The Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Controlled Evaluation (ADVANCE) – the benefits of hyperglycaemia intensive treatment in patients with type 2 diabetes mellitus. Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review, pp.254-259.
MLA
Drzewoski, Józef. "The Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Controlled Evaluation (ADVANCE) – the benefits of hyperglycaemia intensive treatment in patients with type 2 diabetes mellitus." Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review, 2008, pp. 254-259.
Vancouver
Drzewoski J. The Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Controlled Evaluation (ADVANCE) – the benefits of hyperglycaemia intensive treatment in patients with type 2 diabetes mellitus. Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review. 2008:254-259.
W pracy omówiono wyniki ramienia hipoglikemizującego badania The Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Controlled Evaluation (ADVANCE) i skonfrontowano je z wynikami badania Action to Control CardiOvascular Risk in Diabetes (ACCORD) i Veterans Affairs Diabetes Trial (VADT).
Słowa kluczowe
ADVANCE, cukrzyca typu 2, leczenie intensywne, leczenie standardowe